The Effect of Vascular Distensibility on Endothelial-Dependent Vasoreactivity in Patients With Systolic Hypertension Before and After Receiving Oral Alagebrium for 8 Weeks.

Trial Profile

The Effect of Vascular Distensibility on Endothelial-Dependent Vasoreactivity in Patients With Systolic Hypertension Before and After Receiving Oral Alagebrium for 8 Weeks.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2008

At a glance

  • Drugs Alagebrium chloride (Primary)
  • Indications Isolated systolic hypertension
  • Focus Pharmacodynamics
  • Sponsors Synvista Therapeutics
  • Most Recent Events

    • 21 Aug 2008 Actual end date (Jan 2006) added as reported by ClinicalTrials.gov.
    • 21 Aug 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top